| GSRX Industries (OTCQB: GSRX) Subsidiary Set to Begin Manufacturing Operations in California |
| |
|
GSRX Industries (OTCQB: GSRX) wholly owned subsidiary, Point Arena Manufacturing, received its provisional manufacturing license for adult and medicinal cannabis products from the California Department of Public Health Manufactured Cannabis Safety Branch.
Why It Matters: The Provisional License replaces the Temporary License granted to Point Arena Manufacturing in April and allows for the commencement of operations at the Company’s new adult and medicinal cannabis products manufacturing business in Point Arena, California. The Type 6 license allows the Company to engage in extraction using a mechanical method or non-volatile solvent (ex: CO2, ethanol, water, or food-grade dry ice, cooking oils or butter), for infusions and for packaging and labeling.
Point Arena Manufacturing will engage primarily in the manufacture of cannabis concentrate products related to vape cartridge filling and fulfillment, and in the manufacture of Dragonglass, the Company’s proprietary edible THC formulation. According to cannabis investment and market research firm Arcview, vaping accounted for 4.2% of the total legal cannabis market in 2015, capturing just $200 million in sales, yet grew to 12.9% of total legal cannabis sales in 2017 ($1.1 billion). By 2021, Arcview predicts that vape sales will surge to a total of $5.3 billion and will account for 25% of all legal cannabis sales.
What’s Next: GSRX’s wholly owned subsidiary, Point Arena Distribution, also received good news last week, with approval from Mendocino County’s Coastal Development Commission to conduct commercial cannabis distribution activities in Point Arena, California. Following a public hearing, the Coastal Development Commission granted unanimous approval of Point Arena Distribution’s application, an important step towards the commencement of operations at the Company’s new adult and medicinal cannabis products manufacturing and distribution business in Point Arena, CA.
Fueled by the tremendous growth in vaping, Point Arena Manufacturing will engage primarily in the manufacture and distribution of cannabis concentrate products related to vape cartridge filling and fulfillment. According to cannabis investment and market research firm Arcview vape cartridges, a once-overlooked product category with sales of less than $100 million in 2014, boasted sales of $2.9 billion in 2018, with sales estimated to reach $8.4 billion in 2022, nearly matching estimated flower sales of $8.5 billion.
Disclosure
GSRX Industries (OTCQB: GSRX) is a client of RedChip Companies. RedChip Companies, Inc. received 1,000,000 registered shares of GSRX for consulting services. Be advised RedChip intends to sell some or all of its shares at any time, including when you are buying.
|
|
| |
|
| Ascendiant Capital Initiates Coverage of Nemaura Medical (NASDAQ: NMRD) with Buy Rating and $3.25 Price Target |
| |
|
Nemaura Medical (NASDAQ: NMRD) received a buy rating and $3.25 price target from analysts at Ascendiant Capital Markets.
Key Quote: “CE mark approval is the most recently achieved milestone. The next milestone we expect is FDA approval. The plan has been to roll out the product in Great Britain, where the company is located, followed by Europe and the U.S. The technology has additional target markets that will also be pursued including continuous lactate monitoring (CLM) which is aimed at elite athletes, those who train to become elites and those that simply want to perform at their best. Our $3.25 price target is derived from synthetic dividend discount model and represents significant upside from the current share price. We believe this valuation balances out the company’s risks with the high growth prospects and large upside opportunity.” — Theodore R. O’Neill, analyst
The Backstory: Nemaura Medical is a medical technology company developing sugarBEAT®, a non-invasive, affordable and flexible, continuous glucose monitoring (CGM) system for adjunctive use by persons with diabetes. SugarBEAT consists of a disposable adhesive skin-patch connected to a rechargeable wireless transmitter that displays glucose readings at regular five-minute intervals via a mobile app. Monitoring glucose is critical for diabetics and until now, the choice has been a finger stick as needed, or to have a sensor placed under the skin for up to 90 days. Nemaura’s technology allows its sensor to be placed on the skin.
Disclosure
Nemaura Medical (NASDAQ: NMRD) is a client of RedChip Companies. NMRD agreed to pay RedChip a monthly cash fee for investor awareness services.
|
|
| |
|
| cbdMD (NYSE American: YCBD) Set to Join Russell 3000 |
| |
|
cbdMD (NYSE American: YCBD) is set to join the Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual reconstitution, effective after the U.S. market opens on July 1, according to a preliminary list of additions posted June 7.
Key Quote: “Inclusion in the Russell 3000 Index is a reflection of the strong growth, execution, and financial performance that has characterized cbdMD during the past year. The increased exposure we gain from inclusion in the Russell indexes will expand awareness of cbdMD among institutional investors and other key stakeholders. Our goal is to build cbdMD into the most recognized CBD brand in America, and based on recent results, we’re in a great position to accomplish this goal. We look forward to sharing our ongoing successes with a wider audience moving forward.” — Martin A. Sumichrast, Chairman and CEO
The Backstory: Annual Russell indexes reconstitution captures the 4,000 largest US stocks as of May 10, ranking them by total market capitalization. Membership in the US all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings and style attributes.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $9 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Disclosure
cbdMD (NYSE American: YCBD) is a client of RedChip Companies. YCBD agreed to pay RedChip a monthly cash fee of between $5,000 and $15,000, and 5,000 shares of Rule 144 stock for RedChip investor awareness services. Additionally, the CEO of RedChip Companies owns 13,500 shares of YCBD.
|
|
| |
|
| MYnd Analytics (NASDAQ: MYND) to Hold Group Call Wednesday at 11 am ET |
| |
|
Robin L. Smith, Chairman of the Board of MYnd Analytics Inc (NASDAQ: MYND), a technology-enabled telepsychiatry and teletherapy company providing enhanced access to behavioral-health services, and Patrick Herguth, Chief Executive Officer of MYND, will hold a group call Wednesday, June 26, 2019 at 11 am Eastern/8 am Pacific. Duration: 20 minutes.
In the call, which will not be archived, Ms. Smith and Mr. Herguth will discuss recent developments and key upcoming milestones. To join the call, which is free of charge, please phone RedChip Specialist Craig Brelsford at (407) 571-0902, or write to craig@redchip.com.
About MYnd Analytics Inc (NASDAQ: MYND)
• Market cap: $12 million
• The MYnd Psychiatric EEG Evaluation Registry (PEER) is a predictive analytics decision-support tool that helps physicians reduce trial-and-error treatment for behavioral health conditions. PEER provides the physician a personalized care plan with recommended treatment options based on a patient's unique brain markers, reducing both cost and time of treatment
• MYND's wholly owned subsidiary, Arcadian Telepsychiatry Services, LLC, provides a suite of complementary telemedicine services that can be combined with PEER, among them telepsychiatry, teletherapy, digital patient screening, curbside consultation, and on-demand services
• MYND's customers include major health plans, health systems, and community-based organizations. MYND's tele-behavioral health services are now offered through the Magellan Healthcare provider network—evidence of the power of MYND's technology and its best-in-class platform
• In January 2019, MYND announced a merger agreement with Emmaus Life Sciences, developer of the first FDA-approved drug for the treatment of sickle-cell disease. MYND shareholders will own 5.9% of Emmaus, and MYnd Analytics will be spun off as an independent company, providing shareholders with upside potential in two exciting growth stories
• Dawson James has independent coverage on MYND. Target: $4
View Investor Deck: www.slideshare.net/RedChip/mynd-presentation-632019
More Information: myndanalytics.com, www.myndanalyticsinfo.com/
Disclosure
MYnd Analytics (NASDAQ: MYND) is a client of RedChip Companies, Inc. MYND agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services
|
|
| |
|
| Surge in Orders for LALPINA CBD Water Temporarily Crashes SinglePoint’s (OTCQB: SING) Retail Site |
| |
|
SinglePoint (OTCQB: SING) ecommerce site SingleSeed.com received an overwhelming response for LALPINA CBD Water, a brand of American Premium Water Company. LALPINA CBD has consistently been a top seller on the site and multiple reorders have occurred. Unfortunately, the website saw so much traffic last week that it crashed and caused a delay in ordering. The site has since been restored and more resources added to accommodate the growing demand.
Key Quote: “LALPINA CBD has been a great product on our site. And this response for their product is very exciting for SingleSeed and LALPINA CBD. We look forward to continuing our great relationship and shipping orders of LALPINA CBD to all customers. We have resolved the issue and including additional precautions to avoid another outage. Thank you to all the customers supporting LALPINA and SingleSeed.” — Will Ralston, President
The Backstory: SinglePoint is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base. Through SingleSeed, the company is providing products and services to the cannabis industry.
Disclosure
SinglePoint, Inc. (OTCQB: SING) is a client of RedChip Companies, Inc. SING agreed to pay RedChip Companies, Inc. a monthly cash fee for RedChip investor awareness services and consulting services
|
|
| |
|
| Digital Ally (NASDAQ: DGLY) Pre-Sales Exceed Expectations for New, Revolutionary EVO-HD In-Car System |
| |
|
Digital Ally (NASDAQ: DGLY), which develops, manufactures, and markets advanced digital technology products for law enforcement, homeland security and commercial security applications, is pleased to announce that pre-sale demand for its newest in-car system is greater than expected, with over 70 law enforcement agencies ready to receive EVO-HD during the first phase of shipping scheduled to begin in late June. The EVO-HD is the most advanced, compact and easy to install system from Digital Ally with built-in, patented auto-activation technology.
EVO-HD is a complete video solution for any situation, designed to be flexible, customizable and reliable. The system has combined many features such as Digital Ally’s patented VuLink auto-activation technology and real time diagnostics into one unit that can be custom mounted in any vehicle. With the ability to operate the EVO-HD through the MDT or available monitor, law enforcement departments can keep feature-rich factory rear-view mirrors intact.
Key Quote: “This system was designed not only to meet today’s needs but tomorrow’s as well. What makes EVO-HD unique is its ability to adapt to future technology developments. One example is the much publicized development of 5G cell connectivity. We designed the EVO-HD specifically to integrate this technology once it is widely available.” Stan Ross, CEO of Digital Ally
The Backstory: Digital Ally®, headquartered in Lenexa, KS, specializes in the design and manufacture of the highest quality video recording equipment and video analytic software. Digital Ally pushes the boundaries of technology in industries such as law enforcement, emergency management, commercial fleets, and consumer use. Digital Ally’s complete product solutions include in-car and body cameras, cloud and local management software, and automatic recording technology. These products work seamlessly together and are simple to install and operate. Digital Ally products are sold by domestic direct sales representatives and international distributors worldwide.
Disclosure
Digital Ally, Inc. (NASDAQ: DGLY) is a client of RedChip Companies, Inc. DGLY agreed to pay RedChip Companies, Inc., a monthly cash fee for four (4) months of RedChip investor awareness services.
|
|
| |
|
| Immuron (NASDAQ: IMRN) to Commence US Non-Deal Institutional Investor Roadshow |
| |
|
Immuron (ASX: IMC; NASDQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of many gut mediated pathogens, today is pleased to release to shareholders and investors its latest Company Update presentation ahead of a comprehensive roadshow to investment institutions, analysts and shareholders in the United States, by-CEO Dr. Gary Jacob.
The Backstory: Immuron (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases. Immuron has a novel and safe technology platform with one commercial asset, Travelan®, generating revenue. Immuron’s lead clinical candidate, IMM-124E, is presently in Phase II trials in Severe Alcoholic Hepatitis (SAH) and Paediatric Non-alcoholic Fatty Liver Disease (NAFLD). The company now has plans to develop a U.S. registration dossier for IMM-124E for Travelers’ Diarrhea. Immuron’s second clinical-stage asset, IMM-529, targets Clostridium difficile Infections (CDI), and is presently in a clinical trial in CDI patients. These products, together with the Company’s other preclinical immunotherapy pipeline products currently under development targeting immune-related and infectious diseases, are anticipated to meet pressing needs in the global immunotherapy market.
For more information visit: www.immuron.com
Disclosure
Immuron Ltd. (NASDAQ: IMRN) is a client of RedChip Companies, Inc. IMRN agreed to pay RedChip Companies, Inc. a monthly cash fee for (3) months of investor awareness services.
|
|
| |
|
| Sorrento (NASDAQ: SRNE) Provides Updates on CD38 Immunotherapies and Implementation of Disruptive GMP Manufacturing for ‘Off-The-Shelf’ Cell Therapy |
| |
|
• CD38 Therapeutics Business Unit formed to focus on development of CD38-directed immunotherapies for potential out-licensing, collaboration and/or other strategic considerations
• Clinical “Proof-of-Concept” CD38 CAR-T Phase 1 trial progressing and to be concluded in 2019
• Next-Gen “Off-the-Shelf” CD38 Dimeric Antigen Receptor (“DAR”)-T cell therapy with IND submission targeted for second half of 2019
• CD38 Antibody-Drug Conjugate (“ADC”) IND to be submitted in Q4 2019
• CD38-directed immunotherapies demonstrate potent cytotoxicity in preclinical models and against Daratumumab-resistant multiple myeloma patients’ tumor cells in vitro
• State-of-the-Art cGMP Facility in San Diego fully operational with manufacturing capacity for thousands of allogeneic cell therapy doses per year thus, drastically reducing treatment cost
Clinical Proof-of-concept Study for Anti-CD38 Autologous CAR-T Cell Therapy
The Sorrento suite of anti-CD38 immunotherapies is based on a fully human anti-CD38 antibody mined from the Sorrento G-MAB™ antibody library. This antibody has demonstrated unique functional binding properties, which make it a promising candidate for therapeutic applications. To read the full press release, click here.
The Backstory: Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made possible by its extensive array of immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical-stage immuno-cellular therapies (“CAR-T”), antibody-drug conjugates (“ADC”), and clinical-stage oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for cancer patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule in Resiniferatoxin (“RTX”) and ZTlido®. Resiniferatoxin is completing a Phase 1b trial in terminal cancer patients. ZTlido was approved by US FDA on 02/28/18.
|
|
| |
|
| Piedmont Lithium (NASDAQ: PLL) to Hold Group Call Thursday at 4 pm ET |
| |
|
Keith Phillips, President and CEO of Piedmont Lithium Ltd (NASDAQ: PLL), a company holding a 100% interest in the Piedmont Lithium Project in North Carolina, the only conventional lithium project in the United States, will hold a group call Thursday, June 27, 2019 at 4 pm Eastern/1 pm Pacific. Duration: 20 minutes.
In the call, which will not be archived, Mr. Phillips will discuss recent developments and key upcoming milestones. To join the call, which is free of charge, please phone RedChip Specialist Craig Brelsford at (407) 571-0902, or write to craig@redchip.com.
About Piedmont Lithium Ltd (NASDAQ: PLL)
• Market cap: $80 million
• Holds 100% interest in Piedmont Lithium Project in world-class Carolina Tin-Spodumene Belt, one of the largest lithium provinces in the world, 25 miles west of Charlotte
• The Piedmont Lithium Project enjoys a prime location and exceptional economics. Compared to projects in Australia and Canada, North Carolina offers a lower-cost, lower-tax operating environment. In addition, the Project offers easy access to major high-tech population centers and downstream lithium-processing facilities
• Lithium is on the U.S. government’s critical minerals list, giving the Project significant strategic value as the only conventional U.S. lithium development project
• Benchmarking shows deep undervaluation vs. peers. PLL has an EV/steady-state EBITDA of ~0.3x vs. peers at 1.0x-2.5x
Key Quote: "As the only conventional lithium project in the USA, we have attracted considerable strategic interest and have engaged in initial conversations with parties in the lithium, mining, chemicals, battery, automotive, and private equity sectors." — Keith D. Phillips, President and CEO, PLL
View Investor Deck: www.slideshare.net/RedChip/piedmont-lithium-corporate-presentation-may-2019
PLL Webinar of May 29, 2019: www.redchip.com/events/41/piedmont-lithium-webinar/pll
More Information: piedmontlithium.com, www.pllinfo.com
Disclosure
Piedmont Lithium (PLL) is a client of RedChip Companies, Inc. PLL agreed to pay RedChip Companies, Inc. a monthly cash fee for six (6) months of RedChip investor awareness services.
|
|
| |
|
| Emerald Health Therapeutics (OTCQX: EMHTF) Receives Cultivation License for New-Build Organic Cannabis Operation |
| |
|
Emerald Health Therapeutics (OTCQX: EMHTF) received its initial cultivation license from Health Canada for its new organic cannabis growing facility in Metro Vancouver, BC. Tailor-made for Emerald to produce high-quality organic cannabis, the operation comprises two 78,000 square foot greenhouses and 12 acres (~500,000 square feet) of outdoor cultivation, with potential for an additional 12 acres.
Key Quote: “Organic products appeal to many consumers, including many cannabis users, and we look forward to serving both medical and recreational consumers with our quality organic cannabis products. We designed this new state-of-the-art facility to optimize natural light and with up-to-date energy-efficient climate control systems. We are also using select genetics from our large, proprietary genetic library that we believe are ideally suited for organic greenhouse and outdoor cultivation. With a combination of optimized infrastructure design, carefully selected genetics, and efficient operations, we expect to produce premium organic products with clearly differentiated appeal to consumers. We expect that outdoor cultivation will have a lower cost base than greenhouse production, which we anticipate will contribute to our goal of enhanced profit margins.” — Dr. Avtar Dhillon, President and Executive Chairman
The Backstory: Emerald Health is a Canadian licensed producer of cannabis. Emerald has secured exclusive strategic partnerships for large scale extraction and softgel encapsulation, as well as for proprietary technology to enhance cannabinoid bioavailability. Its team is highly experienced in life sciences, product development, large-scale agri-business, and marketing, and is focused on developing proprietary, value-added cannabis products for medical and adult-use customers. Learn more in our exclusive interview with Emerald’s CFO Rob Hill: https://youtu.be/XnDWHv4BXmE.
|
|
| |
|
| |
| Quote of the Week |
| |
"The single most important way we attempt to manage risk, in any environment, is by seeking to buy stocks very cheaply—we never want to pay too much."
- Bill Hench, Portfolio Manager, Royce Opportunity Funds |
|
|
|
|
|
|
|
| About RedChip |
| |
| RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on small-cap and mid-cap companies. Since 1992, RedChip has delivered concrete, measurable results for its clients through the most comprehensive service platform in the industry for small-cap and mid-cap companies. These services include a worldwide distribution network for its stock research written by analysts holding the CFA designation; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated over 2.3 million unique investor views; quarterly global online institutional and retail investor conferences that reach over 10,000 investors annually; "The RedChip Money Report" television show which airs in 100 million homes across the U.S. on The Family Channel; a weekly newsletter delivered to 60,000 investors; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more. |
| |
| RedChip Disclosure |
| |
RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.
RedChip Visibility is a division of RedChip Companies, Inc. and offers research services to paying clients. In the purview of Section 17(b) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that the RedChip Companies Inc. is an investor relations firm hired by certain Companies to increase investor awareness to the small-cap equity community.
Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print.
We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov and view RedChip’s Disclosures. |
|
| |
|
|
| |
|
|
Copyright © 2019 RedChip Companies, Inc. All Rights Reserved.
You are receiving this message because this email address has signed up to receive News Alerts.
|
|
|
|
|
| | |
